Sugi Predict

Sugi Predict / Compounds / SCHEMBL7426182

SCHEMBL7426182

SCHEMBL7426182

COC(=O)c1ccc2c(Br)nn(C)c2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.43
▸ KDM4E B2RXH2 4/20 0.43
▸ HPGD P15428 3/20 0.43
▸ GLA P06280 3/20 0.43
▸ GAA P10253 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ CASP1 P29466 1/20 0.43
▸ CASP7 P55210 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ CA12 O43570 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ XDH P47989 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ CA14 Q9ULX7 1/20 0.42
▸ NOTUM Q6P988 1/20 0.42
▸ LCK P06239 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29950049 1.00 ALDH1A1 (0.43) ALDH1A1KDM4EHPGDGLAGAA
SCHEMBL30987624 0.88 MAPT (0.44) ALDH1A1KDM4EHPGDGLAGAA
SCHEMBL20604896 0.88 MAPT (0.44) ALDH1A1KDM4EHPGDGLAGAA
Methyl Nicotinate SCHEMBL30617266 0.88 ALDH1A1 (0.57) ALDH1A1KDM4EMAPTHSD17B10TSHR
SCHEMBL23559707 0.84 ADORA2A (0.47) ALDH1A1KDM4EHPGDGLAGAA
SCHEMBL31632926 0.83 HCAR3 (0.46) ALDH1A1KDM4EHPGDJMJD6PARP1
SCHEMBL24337979 0.82 CA12 (0.46) ALDH1A1KDM4EHPGDGLAGAA
SCHEMBL23559702 0.82 KDM4E (0.50) ALDH1A1KDM4EHPGDGLAGAA
SCHEMBL24338456 0.82 GLA (0.44) ALDH1A1KDM4EHPGDGLAGAA
SCHEMBL29491274 0.82 CA12 (0.46) ALDH1A1KDM4EHPGDGLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250354195-A1 METHOD OF SCREENING UNIV DUNDEE (GB) 2025-11-20 — — US disclosed
US-12144816-B2 Substituted indole Mcl-1 inhibitors VANDERBILT UNIVERSITY (US) 2024-11-19 — — US disclosed
CN-115515956-B Benzimidazole derivative, and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2024-06-25 — — CN disclosed
EP-4292662-A2 SUBSTITUTED INDOLE MCL-1 INHIBITORS Vanderbilt University (US) 2023-12-20 — — EP disclosed
CN-110506038-B Pesticidal compounds 巴斯夫欧洲公司 2023-11-24 — — CN disclosed
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY 2023-10-19 — — US disclosed
EP-3423435-B1 SUBSTITUTED INDOLE MCL-1 INHIBITORS UNIV VANDERBILT (US) 2023-08-23 — — EP disclosed
EP-3601231-B1 PESTICIDAL COMPOUNDS BASF SE (DE) 2023-05-10 — — EP disclosed
US-11596639-B2 Substituted indole Mcl-1 inhibitors VANDERBILT UNIVERSITY (US) 2023-03-07 — — US disclosed
CN-115515956-A Benzimidazole derivative and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2022-12-23 — — CN disclosed
WO-2018177781-A1 PESTICIDAL COMPOUNDS BASF SE (DE) 2018-10-04 — — WO disclosed
WO-2017184658-A1 ACYL SULFONAMIDE NaV1.7 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2017-10-26 — — WO disclosed
WO-2017184658-A1 ACYL SULFONAMIDE NaV1.7 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2017-10-26 — — WO disclosed
US-6489333-B2 HETEROCYCLIC COMPOUNDS CONTAINING A GUANIDINE MIMIC, FOR INHIBITION OF CELL ADHESION, TREATMENT OF ANGIOGENESIS DISORDERS, INFLAMMATION, CANCER METASTASIS, DIABETIC RETINOPATHY, THROMBOSIS, RESTENOSIS, MACULAR DEGENERATION BRISTOL - MEYERS SQUIBB PHARMA COMPANY 2002-12-03 — — US disclosed
US-20010044535-A1 Integrin antagonists BRISTOL-MYERS SQUIBB PHARMA COMPANY 2001-11-22 — — US disclosed
EP-1054871-A2 PYRIMIDINES AND TRIAZINES AS INTEGRIN ANTAGONISTS Du Pont Pharmaceuticals Company (US) 2000-11-29 — — EP disclosed
WO-1999050249-A2 PYRIMIDINES AND TRIAZINES AS INTEGRIN ANTAGONISTS DU PONT PHARMACEUTICALS COMPANY (US) 1999-10-07 — — WO disclosed
EP-0939757-A1 NOVEL INTEGRIN RECEPTOR ANTAGONISTS Dupont Pharmaceuticals Company (US) 1999-09-08 — — EP disclosed
US-5760028-A TREATING CANCER METASTASIS, DIABETIC RETINOPATHY, NEOVASCULAR GLAUCOMA, THROMBOSIS, RESTENOSIS, OSTEOPOROSIS, MACULAR DEGENERATION THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1998-06-02 — — US disclosed
WO-1997023480-A1 NOVEL INTEGRIN RECEPTOR ANTAGONISTS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-07-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12144816-B2 Substituted indole Mcl-1 inhibitors MCL1, BCL2L1, BCL9 ALDH1A1 2556/4885KDM4E 1156/4885HPGD 3190/4885
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, BCL9 ALDH1A1 2556/4885KDM4E 1156/4885HPGD 3190/4885
US-20010044535-A1 Integrin antagonists ITGB3, VCAM1, ITGB2 ALDH1A1 2216/4885KDM4E 3935/4885HPGD 3468/4885
US-20250354195-A1 METHOD OF SCREENING PAICS, COASY, ABCG2 ALDH1A1 275/4885KDM4E 4166/4885HPGD 1782/4885
US-11596639-B2 Substituted indole Mcl-1 inhibitors MCL1, BCL2L1, BCL9 ALDH1A1 2556/4885KDM4E 1156/4885HPGD 3190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.